Ixazomib联合达雷妥尤单抗及低剂量地塞米松治疗虚弱初诊多发性骨髓瘤:HOVON 143研究
诱导总缓解率78%,中位随访22.9个月,中位无进展生存期13.8个月,12个月总生存率78%。51%患者诱导期提前终止,因毒性9%、死亡9%,生活质量和诱导3周期后即有临床意义改善,但毒性和早期死亡影响生存。
要点
- Ixa-Dara-dex在虚弱初诊骨髓瘤中诱导缓解率78%,但51%提前终止诱导。
- 中位PFS 13.8个月,12个月OS 78%,因毒性与早期死亡影响生存。
- 仅年龄>80岁虚弱者PFS 21.6个月、12个月OS 92%,其他虚弱参数者预后更差。
核心结论
- Ixa-Dara-dex在虚弱初诊多发性骨髓瘤中诱导缓解率高且改善生活质量,但毒性和早期死亡导致的治疗终止仍是问题,不同虚弱亚组结局异质。
主要发现
- 诱导总缓解率78%。
- 中位随访22.9个月,中位无进展生存期13.8个月,12个月总生存率78%。
- 仅年龄>80岁虚弱者中位PFS 21.6个月、12个月OS 92%;基于其他虚弱参数且≤80岁者中位PFS 13.8个月、12个月OS 78%;>80岁且有其他虚弱参数者中位PFS 10.1个月、12个月OS 70%。
- 51%患者诱导提前终止:6%不依从、9%毒性、9%死亡(8%在2个月内,其中80%因毒性)。
- 生活质量在诱导治疗期间改善,3周期后即达临床意义。
临床怎么用
- 对虚弱初诊多发性骨髓瘤可考虑Ixa-Dara-dex,但需密切监测毒性和早期死亡风险。
- 治疗决策应结合虚弱亚组特征,仅年龄>80岁者结局较好,其他虚弱参数者预后更差。
局限性
- 不同虚弱亚组结局异质,需在未来研究中考虑以精确指导治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Frail patients with newly diagnosed multiple myeloma have an inferior outcome, mainly because of a high discontinuation rate due to toxicity. We designed a phase II trial specifically for frail patients, evaluating the efficacy and tolerability of ixazomib-daratumumab-low-dose-dexamethasone (Ixa-Dara-dex). METHODS: Sixty-five patients, who were frail according to the International Myeloma Working Group frailty index, were treated with nine induction cycles Ixa-Dara-dex followed by maintenance with Ixa-Dara for a maximum of 2 years. RESULTS: The overall response rate on induction therapy was 78%. After a median follow-up of 22.9 months, median progression-free survival (PFS) was 13.8 months and 12-month overall survival (OS) was 78%. Median PFS and 12-month OS were 21.6 months and 92% in patients who were frail based on age > 80 years alone, versus 13.8 months and 78%, and 10.1 months and 70% in patients who were frail based on additional frailty parameters either ≤ 80 or > 80 years of age, respectively. In 51% of patients, induction therapy had to be discontinued prematurely, of which 6% because of noncompliance to study treatment, 9% because of toxicity, and 9% because of death (8% within 2 months, of which 80% because of toxicity). Quality of life improved during induction treatment, being clinically meaningful already after three induction cycles. CONCLUSION: Ixa-Dara-dex lead to a high response rate and improved quality of life. However, treatment discontinuation because of toxicity and early mortality, negatively influencing PFS and OS, remains a concern in frail patients. The outcome was heterogeneous across frail subpopulations. This should be taken into account in the design and interpretation of future studies in frail patients, to pave the way for more precise treatment guidance.
引用
- Stege CAM, Nasserinejad K, van der Spek E, et al. Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study. J Clin Oncol. 2021. PMID: 33945289. doi:10.1200/JCO.20.03143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。